F&V Capital Management LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 78,350 shares of the biopharmaceutical company’s stock after purchasing an additional 1,370 shares during the quarter. Gilead Sciences comprises approximately 2.9% of F&V Capital Management LLC’s investment portfolio, making the stock its 13th largest holding. F&V Capital Management LLC’s holdings in Gilead Sciences were worth $5,613,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Welch Investments LLC purchased a new position in Gilead Sciences during the 3rd quarter worth $108,000. Wealthcare Advisory Partners LLC purchased a new position in Gilead Sciences during the 3rd quarter worth $133,000. Horan Capital Advisors LLC. purchased a new position in Gilead Sciences during the 3rd quarter worth $144,000. Hanson & Doremus Investment Management boosted its holdings in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $147,000. 76.47% of the stock is owned by institutional investors and hedge funds.
In other news, Director Gayle E. Wilson sold 60,000 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the sale, the director now directly owns 182,258 shares in the company, valued at $14,201,543.36. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the sale, the executive vice president now owns 70,988 shares in the company, valued at $5,298,544.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 418,333 shares of company stock worth $32,742,108. Company insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $81.82 on Thursday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The stock has a market capitalization of $106,850.00, a PE ratio of 23.51, a P/E/G ratio of -1.83 and a beta of 1.22. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the prior year, the business posted $2.70 earnings per share. The company’s revenue was down 18.7% on a year-over-year basis. equities analysts anticipate that Gilead Sciences, Inc. will post 6.24 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.79%. Gilead Sciences’s dividend payout ratio is currently 59.77%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.